AKBA
Income statement / Annual
Last year (2025), Akebia Therapeutics Inc.'s total revenue was $236.20 M,
an increase of 47.46% from the previous year.
In 2025, Akebia Therapeutics Inc.'s net income was -$5.35 M.
See Akebia Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$236.20 M |
$160.18 M |
$194.62 M |
$292.48 M |
$211.65 M |
$294.64 M |
$335.00 M |
$207.74 M |
$177.98 M |
$1.54 M |
| Cost of Revenue |
$39.46 M
|
$63.18 M
|
$74.15 M
|
$22.50 M
|
$81.49 M
|
$63.96 M
|
$145.34 M
|
$7.69 M
|
$617.00 K
|
$115.79 M
|
| Gross Profit |
$196.73 M
|
$97.00 M
|
$120.47 M
|
$269.99 M
|
$130.16 M
|
$230.68 M
|
$189.67 M
|
$200.06 M
|
$177.37 M
|
-$114.25 M
|
| Gross Profit Ratio |
0.83
|
0.61
|
0.62
|
0.92
|
0.61
|
0.78
|
0.57
|
0.96
|
1
|
-74.43
|
| Research and Development Expenses |
$62.36 M
|
$37.65 M
|
$63.08 M
|
$165.99 M
|
$147.85 M
|
$218.49 M
|
$322.97 M
|
$291.07 M
|
$230.89 M
|
$115.79 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$131.90 M
|
$165.94 M
|
$149.10 M
|
$143.46 M
|
$86.56 M
|
$27.01 M
|
$22.21 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$100.23 M
|
$6.70 M
|
$8.20 M
|
$5.00 M
|
$6.00 M
|
$500.00 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$107.48 M
|
$106.55 M
|
$100.23 M
|
$138.60 M
|
$174.14 M
|
$154.10 M
|
$149.46 M
|
$87.06 M
|
$27.01 M
|
$22.21 M
|
| Other Expenses |
$3.40 M
|
$3.28 M
|
$3.42 M
|
$46.18 M
|
$72.67 M
|
$235.92 M
|
$3.53 M
|
$0.00
|
$204.00 K
|
-$188.00 K
|
| Operating Expenses |
$173.24 M
|
$147.48 M
|
$166.73 M
|
$350.77 M
|
$394.66 M
|
$608.51 M
|
$475.95 M
|
$378.20 M
|
$257.90 M
|
$138.00 M
|
| Cost And Expenses |
$212.70 M
|
$210.65 M
|
$240.88 M
|
$373.26 M
|
$476.15 M
|
$672.47 M
|
$621.29 M
|
$385.88 M
|
$257.90 M
|
$138.00 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.19 M
|
$6.15 M
|
$2.80 M
|
$901.00 K
|
| Interest Expense |
$24.18 M
|
$18.19 M
|
$6.03 M
|
$15.69 M
|
$19.94 M
|
$8.87 M
|
$1.40 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.27 M
|
$37.50 M
|
$37.63 M
|
$37.70 M
|
$37.97 M
|
$34.69 M
|
$36.42 M
|
$2.42 M
|
$617.00 K
|
$296.00 K
|
| EBITDA |
$21.73 M |
-$13.72 M |
-$8.27 M |
$3.06 M |
-$189.91 M |
-$139.83 M |
-$249.87 M |
-$178.09 M |
-$76.06 M |
-$136.16 M |
| EBITDA Ratio |
0.09
|
-0.09
|
-0.04
|
0.01
|
-0.9
|
-0.47
|
-0.75
|
-0.86
|
-0.43
|
-88.71
|
| Operating Income Ratio |
0.1
|
-0.32
|
-0.24
|
-0.28
|
-1.25
|
-1.28
|
-0.85
|
-0.86
|
-0.45
|
-88.9
|
| Total Other Income/Expenses Net |
-$27.22 M
|
-$18.94 M
|
-$5.67 M
|
-$13.45 M
|
-$17.52 M
|
-$7.02 M
|
-$2.00 K
|
$6.24 M
|
$3.00 M
|
$713.00 K
|
| Income Before Tax |
-$3.72 M
|
-$69.41 M
|
-$51.93 M
|
-$94.23 M
|
-$282.02 M
|
-$384.84 M
|
-$286.29 M
|
-$171.90 M
|
-$76.91 M
|
-$135.75 M
|
| Income Before Tax Ratio |
-0.02
|
-0.43
|
-0.27
|
-0.32
|
-1.33
|
-1.31
|
-0.85
|
-0.83
|
-0.43
|
-88.43
|
| Income Tax Expense |
$1.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$6.63 M
|
-$28.34 M
|
-$2.80 M
|
-$901.00 K
|
| Net Income |
-$5.35 M
|
-$69.41 M
|
-$51.93 M
|
-$94.23 M
|
-$282.02 M
|
-$384.84 M
|
-$279.66 M
|
-$171.90 M
|
-$76.91 M
|
-$135.75 M
|
| Net Income Ratio |
-0.02
|
-0.43
|
-0.27
|
-0.32
|
-1.33
|
-1.31
|
-0.83
|
-0.83
|
-0.43
|
-88.43
|
| EPS |
-0.0208 |
-0.33 |
-0.28 |
-0.58 |
-1.48 |
-2.53 |
-2.36 |
-1.47 |
-1.77 |
-3.6 |
| EPS Diluted |
-0.0208 |
-0.33 |
-0.28 |
-0.58 |
-1.48 |
-2.53 |
-2.36 |
-1.47 |
-1.77 |
-3.6 |
| Weighted Average Shares Out |
$257.16 M
|
$210.95 M
|
$187.47 M
|
$182.78 M
|
$165.95 M
|
$138.46 M
|
$118.40 M
|
$116.89 M
|
$43.50 M
|
$37.72 M
|
| Weighted Average Shares Out Diluted |
$257.16 M
|
$210.95 M
|
$187.47 M
|
$182.78 M
|
$165.95 M
|
$138.46 M
|
$118.40 M
|
$116.89 M
|
$43.50 M
|
$37.72 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
